FUM Stock Overview
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Futura Medical plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.35 |
| 52 Week High | UK£0.67 |
| 52 Week Low | UK£0.23 |
| Beta | 1.24 |
| 1 Month Change | -6.84% |
| 3 Month Change | 16.83% |
| 1 Year Change | -28.05% |
| 3 Year Change | -21.33% |
| 5 Year Change | 67.77% |
| Change since IPO | -50.49% |
Recent News & Updates
We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth
Apr 17
Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation
Jan 05Recent updates
We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth
Apr 17Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation
Jan 05Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?
Jul 28We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully
Mar 18We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate
Sep 25Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation
May 10We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow
Jan 10What We Learned About Futura Medical's (LON:FUM) CEO Compensation
Dec 21
Shareholder Returns
| FUM | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -0.3% | 8.3% | 2.2% |
| 1Y | -28.0% | 4.9% | 0.9% |
Price Volatility
| FUM volatility | |
|---|---|
| FUM Average Weekly Movement | 14.6% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: FUM's share price has been volatile over the past 3 months.
Volatility Over Time: FUM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 12 | James Barder | www.futuramedical.com |
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel.
Futura Medical plc Fundamentals Summary
| FUM fundamental statistics | |
|---|---|
| Market cap | UK£106.71m |
| Earnings (TTM) | -UK£6.51m |
| Revenue (TTM) | UK£3.10m |
34.4x
P/S Ratio-16.4x
P/E RatioIs FUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FUM income statement (TTM) | |
|---|---|
| Revenue | UK£3.10m |
| Cost of Revenue | UK£1.33m |
| Gross Profit | UK£1.77m |
| Other Expenses | UK£8.29m |
| Earnings | -UK£6.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 57.22% |
| Net Profit Margin | -210.03% |
| Debt/Equity Ratio | 0% |
How did FUM perform over the long term?
See historical performance and comparison